Diffuse Large B Cell Lymphoma, Esophageal Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer, Solid Tumor, Adult
Conditions
Keywords
cancer, solid tumor, DLBCL, CX-2029, PROBODY™ Therapeutic, Drug Conjugate, Antibody drug conjugate, CD71, Transferrin receptor 1
Brief summary
The purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029 in adult subjects with metastatic or locally advanced unresectable solid tumors or diffuse large B-cell lymphoma (DLBCL). The antitumor activity of CX-2029 will be evaluated in subjects with head and neck squamous cell carcinoma (HNSCC), DLBCL, non-small cell lung cancer (NSCLC) (squamous cell histology only), or esophageal (esophageal adenocarcinoma \[EAC\], esophageal squamous cell carcinoma \[ESCC\], or gastroesophageal \[GE\] junction) cancer. PROCLAIM: PRObody CLinical Assessment In Man CX-2029 clinical trial 001 PROBODY is a trademark of CytomX Therapeutics, Inc
Detailed description
This is an open-label, Phase 1-2, first-in-human study for CX-2029 in subjects with metastatic or locally advanced unresectable solid tumors or Diffuse large B-cell lymphoma (DLBCL) without approved life-prolonging treatment options for their malignancy. The study is divided into 3 parts (arms), as follows: * Part A: Dose escalation and determination of the Maximum tolerated dose (MTD) and/or Recommended Phase 2 dose (RP2D) * Part B: Characterization of CX-2029 in the Tumor microenvironment (TME) in subjects with select tumor types using previously cleared dose levels from Part A * Part C: Expansions in select tumor types at the MTD/RP2D as established in Part A
Interventions
DRUGCX-2029
CX-2029 Monotherapy
Sponsors
CytomX Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced unresectable tumors 2. Patients demonstrating disease progression after treatment with approved therapies that are known to confer life-prolonging benefit, or who are intolerant to or have declined treatment 3. Agreement to provide mandatory archival tissue or fresh biopsy 4. At least 18 years of age 5. For Arm A, histologically or cytologically confirmed metastatic or locally advanced unresectable solid tumor 6. For Arms B and C, histologically or cytologically confirmed metastatic or locally advanced unresectable HNSCC, DLBCL, NSCLC (squamous cell histology only), or esophageal (EAC, ESCC, or GE junction) cancer 7. Additional inclusion criteria may apply
Exclusion criteria
1. Neuropathy \> Grade 1 2. Serious concurrent illness, including clinically relevant active infection 3. Clinically significant iron metabolism disorders (eg, sickle cell anemia) 4. Significant cardiac disease such as recent myocardial infarction 5. History of multiple sclerosis or other demyelinating disease, Eaton-Lambert syndrome (para-neoplastic syndrome), history of hemorrhagic or ischemic stroke within the last 6 months, or alcoholic liver disease; 6. Non-healing wound(s) or ulcer(s) except for ulcerative lesions caused by the underlying neoplasm; 7. History of severe allergic or anaphylactic reactions to previous monoclonal antibody therapy; 8. Currently receiving anticoagulation therapy with warfarin; 9. Major surgery (requiring general anesthesia) within 3 months prior to dosing. 10. Hepatic impairment which is moderate (Child-Pugh B) or severe (Child-Pugh C) 11. Transfusion dependent anemia with transfusion dependency of ≥3 months 12. Use of iron chelators 13. Additional
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of subjects experiencing a dose-limiting toxicity at various dose levels when given CX-2029 as a monotherapy | 21 days (dose-limiting toxicity period) |
Secondary
| Measure | Time frame |
|---|---|
| The percentage of subjects experiencing anti-cancer activity (ORR) at various dose levels when given CX-2029 as a monotherapy | 2 years |
Countries
South Korea, Spain, United Kingdom, United States
Outcome results
None listed